Victor DeNoble, PhD

 Victor DeNoble, PhD

 

Victor DeNoble, PhD

 
Friday, April 13, 2012
9 am – 12 pm (repeats from 2 - 5 pm)
Recommended for: Dental Team
ODA Course
3 CE Credits
 
 

 

 

 

Inside the Darkside and Drug Addiction: It’s All in Your Brain

The first part of the program will discuss the research conducted at Philip Morris to identify a nicotine substitute that maintained the addictive properties of nicotine while reducing cardiovascular risk.

The second part of the program will review groundbreaking discoveries about the brain that have revolutionized our understanding of drug addiction. Despite these advances in science, many people do not understand how drugs change the brain to produce drug addiction. This program aims to address the knowledge gap by providing scientific information about the disease, including the many harmful consequences of drug abuse. We will first review the neuroanatomical and neurochemical mechanisms of drug addiction. We will then discuss how the most frequently used addictive drugs produce changes the brain. For each of these drugs, both the central and peripheral side effects will be explored, as well as the long- and short-term effects on biological systems.

At the conclusion of this course, attendees will be able to:
  • Discuss the pharmacological research on nicotine addiction conducted within the Philip Morris Research Facility
  • Discuss the biological substrates of drug addiction
  • Discuss the research on the biological changes produced in the brain by various addictive drugs

 

 

Dr. DeNoble has a Doctorate in Experimental Psychology from Adelphi University, NY and two postdoctoral fellowships from NIAAA and NIDA.  He was recruited by Philip Morris to study the behavioral and physiological effects of nicotine on the brain.  He subsequently conducted drug discovery research in CNS diseases for the pharmaceutical industry.  In 1994, after a congressional release from a confidentially agreement with Philip Morris, he testified before Congress and became a key witness in the federal government’s case against the tobacco industry. Currently, he is the Vice President of Hissho, Inc., a scientific and medical communications company.